The ROSA is a novel rating instrument for assessment of symptoms severity of Alzheimer’s disease in medical practice and clinical research.

Pierrel Research Europe has significantly contributed to the ROSA development and validation. Our expertise in methodology of scale development and support for validation of the ROSA scale has recently been acknowledged in the article "Validation of the Relevant Outcome Scale for Alzheimer’s disease: a novel multi-domain assessment for daily medical practice" (Alzheimer’s Therapy & Research 2011, 3, 27).

The ROSA trial (‘Open-label, single-arm, multi-center validation study of the Relevant Outcome Scale for Alzheimer Patients in patients with dementia of Alzheimer’s type treated with memantine over a 3 months period’), which primary objective was to investigate the validity and reliability of the newly developed instrument, has been financed by Merz Pharmaceuticals GmbH, Frankfurt, Germany, and realized in a successful collaboration with Pierrel Research Europe GmbH, Essen, Germany. Pierrel Research Europe has been responsible for the conduction, monitoring, and data management of the trial as well as for reporting of trial results.

Pierrel Research is proud of the successful achievement of all trial goals, which confirms once again our extensive expertise and proficiency in neurological studies and scale development.